Ansbert Gadicke
Founder bij MPM BioImpact, Inc
Oorsprong van het eerstegraads netwerk van Ansbert Gadicke
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
MPM BioImpact, Inc
 MPM BioImpact, Inc Investment ManagersFinance MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts.
110
| Private Company | Investment Managers | 110 |
| Holding Company | Biotechnology | 42 | |
The Boston Consulting Group, Inc.
 The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Boston Consulting Group, Inc. engages in the provision of management consulting services. It specializes in automotive and mobility; biopharmaceuticals; consumer products; education; oil and gas; power and utilities; engineered products and infrastructure; financial institutions; and health care payers, providers, and services. It offers big data and advanced analytics; change management; client learning and enablement; and corporate development and financial services. The company was founded by Bruce Doolin Henderson in 1963 and is headquartered in Boston, MA.
40
| Private Company | Miscellaneous Commercial Services | 40 |
| Subsidiary | Pharmaceuticals: Major | 29 | |
| Public Company | Pharmaceuticals: Major | 23 | |
| Subsidiary | Pharmaceuticals: Major | 23 | |
Pharmasset, Inc.
 Pharmasset, Inc. Pharmaceuticals: OtherHealth Technology Pharmasset, Inc. developed drugs to treat viral infections. It focued in the development of oral therapeutics for the treatment of hepatitis C virus (HCV) infection. The company was founded in 1998 and was headquartered in Princeton, NJ.
19
| Subsidiary | Pharmaceuticals: Other | 19 |
| Public Company | Biotechnology | 16 | |
| Subsidiary | Pharmaceuticals: Major | 15 | |
PharmAthene, Inc. /Old/
 PharmAthene, Inc. /Old/ BiotechnologyHealth Technology PharmAthene, Inc. develops biotherapeutics to address biological pathogens and chemicals. It provides clinical and preclinical development for Bacillus anthracis a therapeutic anti-toxin for treatment of symptomatic patients infected with anthrax monoclonal. The company was founded in 2001 and is located in Annapolis, MD.
14
| Extinct | Biotechnology | 14 |
| Public Company | Biotechnology | 14 | |
| Public Company | Biotechnology | 13 | |
Reunion Neuroscience, Inc.
 Reunion Neuroscience, Inc. BiotechnologyHealth Technology Reunion Neuroscience, Inc. operates drug discovery and development business. Its novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company was founded on October 1, 2020 and is headquartered in Toronto, Canada.
13
| Public Company | Biotechnology | 13 |
Bioimpact Capital LLC
 Bioimpact Capital LLC Investment ManagersFinance MPM BioImpact LLC (MPM BioImpact) is a venture capital firm a subsidiary of MPM Bioimpact Inc founded in 1996. The firm is headquartered in Cambridge, Massachusetts.
12
| Private Company | Investment Managers | 12 |
| Public Company | Biotechnology | 11 | |
MPM BioEquities Adviser LLC
 MPM BioEquities Adviser LLC Investment ManagersFinance Founded in 1997 by Ansbert Gadicke and Luke Evnin, MPM BioEquities Adviser LLC is a hedge fund manager located in South San Francisco, California with an additional office in Boston. The firm is a subsidiary of MPM Capital LP, a private equity firm.
10
| Extinct | Investment Managers | 10 |
ElevateBio LLC
 ElevateBio LLC BiotechnologyHealth Technology ElevateBio LLC is a biotechnology holding company, which creates and operates a broad portfolio of cell and gene therapy companies. It builds single and multi-product companies by providing scientific founders with bench-to-bedside capabilities including scientists, manufacturing facilities, drug developers, and commercial expertise. The company was founded by David L. Hallal, Vikas Sinha, and Mitchell H. Finer and is headquartered in Cambridge, MA.
8
| Holding Company | Biotechnology | 8 |
Orna Therapeutics, Inc.
 Orna Therapeutics, Inc. BiotechnologyHealth Technology Orna Therapeutics, Inc. is a biotechnology company that designs and delivers fully engineered circular RNA therapeutics to treat diseases. Orna Therapeutics is based in Cambridge, MA, and has subsidiaries in the United States. The company's proprietary platform combines novel technology to create RNA that drives protein expression with validated and unique delivery solutions. Orna has many advantages over traditional approaches, including simplified production, improved formulatability, and superior protein expression. The company was founded by Daniel Anderson, Raffaella Squilloni, Alex Wesselhoeft, and the CEO is Thomas M. Barnes.
7
| Holding Company | Biotechnology | 7 |
Mindset BioPharmaceuticals Ltd.
 Mindset BioPharmaceuticals Ltd. Medical/Nursing ServicesHealth Services Mindset BioPharmaceuticals Ltd. develops disease modifying therapies. It specializes in molecular neuropharmacology, behavioral science, clinical neurology, drug delivery, and biopharmaceutical development. The company was founded by Daniel G. Chain in February 1997 and is headquartered in Jerusalem, Israel.
6
| Private Company | Medical/Nursing Services | 6 |
Mitobridge, Inc.
 Mitobridge, Inc. BiotechnologyHealth Technology Mitobridge, Inc. operates as a biopharmaceutical company. It focuses on the development and discovery of products for mitochondrial function. The firm also offers treatments for genetic, metabolic, and neurodegenerative disorders as well as diseases and conditions of aging. The company was founded by Kazumi Shiosaki, Andrew Dillin, Ronald M. Evans, Johan Auwerx and Robert H. Horvitz in October 2011 and is headquartered in Cambridge, MA.
4
| Subsidiary | Biotechnology | 4 |
Cullinan Pearl Corp.
 Cullinan Pearl Corp. BiotechnologyHealth Technology Part of Otsuka Holdings Co., Ltd., Cullinan Pearl Corp. is a private company that develops an orally available tyrosine kinase inhibitor. The company is based in Cambridge, MA. The CEO of the company is Nadim Ahmed. Cullinan Pearl was acquired by Taiho Pharmaceutical Co., Ltd. from Cullinan Oncology, Inc. on June 23, 2022 for $405 million.
2
| Subsidiary | Biotechnology | 2 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Ansbert Gadicke via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
| BAXTER INTERNATIONAL INC. | Medical Specialties | President General Counsel | |
| BRISTOL-MYERS SQUIBB COMPANY | Pharmaceuticals: Major | Corporate Officer/Principal President Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| CELGENE | Biotechnology | President Corporate Officer/Principal Corporate Officer/Principal Director/Board Member | |
| PFIZER, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer Corporate Officer/Principal Corporate Officer/Principal | |
| ASTRAZENECA PLC | Pharmaceuticals: Major | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
| BIOGEN INC. | Pharmaceuticals: Major | Chief Executive Officer Chief Tech/Sci/R&D Officer Sales & Marketing Corporate Officer/Principal | |
| ALEXION PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director of Finance/CFO Chief Executive Officer Compliance Officer | |
| BAYER AG | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member Director/Board Member | |
UBS Securities LLC
 UBS Securities LLC Investment Banks/BrokersFinance UBS Securities LLC is an investment bank and registered broker/dealer headquartered in New York City. The firm was founded in 1998 as UBS Warburg LLC. They are a subsidiary of UBS Americas Holding LLC, ultimately held by UBS Group AG (SWX: UBSG, NYSE: UBS) in Switzerland. UBS Securities is a primary dealer in US Government securities and provides a full range of investment banking services which includes corporate finance, mergers and acquisitions, capital markets, trading and sales, fixed-income, equity research, private banking, underwriting and prime brokerage operations. The firm also provides advisory services and access to capital markets for corporate, institutional, intermediary and alternative asset management clients. | Investment Banks/Brokers | Analyst-Equity Analyst-Equity Corporate Officer/Principal | |
| ACUSPHERE, INC. | Pharmaceuticals: Major | Chief Executive Officer Director/Board Member Director of Finance/CFO | |
Idun Pharmaceuticals, Inc.
 Idun Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology Idun Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the discovery and development of human therapeutics to control apoptosis. The company was founded by John C. Reed, Robert H. Horvitz, and Lawrence C. Fritz in March 1993 and is headquartered in San Diego, CA. | Medical Specialties | Director/Board Member Founder | |
| ONCOSEC MEDICAL INCORPORATED | Medical/Nursing Services | Director/Board Member Director/Board Member | |
| NOVARTIS AG | Pharmaceuticals: Major | Corporate Officer/Principal Corporate Officer/Principal Corporate Officer/Principal | |
| Dartmouth College | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | College/University | Doctorate Degree Masters Business Admin Doctorate Degree Undergraduate Degree Doctorate Degree | |
| University of Cambridge | College/University | Doctorate Degree Doctorate Degree Doctorate Degree | |
| Amherst College | College/University | Undergraduate Degree Undergraduate Degree | |
| Massachusetts Institute of Technology | College/University | Graduate Degree Graduate Degree Corporate Officer/Principal Doctorate Degree Graduate Degree Doctorate Degree Doctorate Degree | |
| Brandeis University | College/University | Undergraduate Degree Undergraduate Degree Undergraduate Degree | |
| Princeton University | College/University | Undergraduate Degree Corporate Officer/Principal Undergraduate Degree Undergraduate Degree | |
| University of Massachusetts | College/University | Doctorate Degree Undergraduate Degree Undergraduate Degree | |
| AVEO PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Corporate Officer/Principal Director/Board Member | |
| THERMO FISHER SCIENTIFIC | Medical Specialties | Director/Board Member Director of Finance/CFO | |
Pharmaceutical Research & Manufacturers of America
 Pharmaceutical Research & Manufacturers of America Pharmaceuticals: MajorHealth Technology Pharmaceutical Research & Manufacturers of America provides pharmaceutical research and biotechnology services. It represents the country’s biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, and more productive lives. The company was founded in 1958 and is headquartered Washington, DC. | Pharmaceuticals: Major | Director/Board Member Director/Board Member Director/Board Member Director/Board Member | |
BioNJ, Inc.
 BioNJ, Inc. Miscellaneous Commercial ServicesCommercial Services BioNJ, Inc. is based in Trenton, NJ. BioNJ, Inc. is a life sciences trade association with nearly 400 member companies. The company supports the discovery, development, and commercialization of therapies and cures that save and improve lives. BioNJ drives capital formation, fosters entrepreneurship, advocates for medical innovation, provides access to talent and education, and offers critical commercial resources. The company also serves as a clearinghouse for funding information and opportunities. The company was founded in 1994 by James J. Marino, Jayne C. Gershkowitz, Abraham Abuchowski. The CEO is Debbie Hart. | Miscellaneous Commercial Services | Director/Board Member Corporate Officer/Principal Director/Board Member | |
| Albert Einstein College of Medicine, Inc. | College/University | Doctorate Degree Corporate Officer/Principal Doctorate Degree | |
| Harvard Medical School | College/University | Director/Board Member Corporate Officer/Principal Doctorate Degree Doctorate Degree Doctorate Degree | |
iTeos Therapeutics SA
 iTeos Therapeutics SA Pharmaceuticals: MajorHealth Technology iTeos Therapeutics SA engages in the discovery of immunomodulators for cancer therapy. It operates as a biotechnology company which focuses on targeting metabolism of the tumor microenvironment through development of small-molecule immunomodulators for cancer treatment. The firm develops small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standards of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints. The company was founded in 2011 by Michel Detheux and Benoit Van den Eynde and is headquartered in Gosselies, Belgium. | Pharmaceuticals: Major | Director/Board Member Chairman Director/Board Member | |
| The Wharton School of the University of Pennsylvania | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
| Harvard Business School | College/University | Masters Business Admin Masters Business Admin Masters Business Admin Masters Business Admin | |
| Stanford Graduate School of Business | College/University | Masters Business Admin Masters Business Admin Masters Business Admin | |
TriNetX, LLC
 TriNetX, LLC Medical/Nursing ServicesHealth Services TriNetX, Inc. provides an online data network for collaborative research. It enables hospitals, academic medical centers, physician networks, practices, and pharmaceuticals to participate in collaborative research and a public and private sustainability model for research informatics. The company was founded by Bard Geesaman in 2013 and is headquartered in Cambridge, MA. | Medical/Nursing Services | Director/Board Member Director/Board Member | |
| KEZAR LIFE SCIENCES, INC. | Biotechnology | Chairman Director/Board Member | |
| ONCORUS, INC. | Biotechnology | Chairman Chief Executive Officer Director/Board Member | |
Maverick Therapeutics, Inc.
 Maverick Therapeutics, Inc. BiotechnologyHealth Technology Maverick Therapeutics, Inc. operates as a preclinical stage biotech company. It develops a novel class of T cell- redirecting antibody therapeutics that have the potential to substantially broaden the range of targets and clinical applications to be used for this ultra-potent mechanism. The company was founded by Robert Dubridge and Patrick A. Baeuerle in 2016 and is headquartered in Brisbane, CA. | Biotechnology | Founder Founder Director/Board Member | |
| ELOXX PHARMACEUTICALS, INC. | Biotechnology | Chief Executive Officer Director of Finance/CFO | |
| WEREWOLF THERAPEUTICS, INC. | Pharmaceuticals: Major | Founder Founder Investor Relations Contact Director/Board Member Director/Board Member | |
Nextpoint Therapeutics, Inc.
 Nextpoint Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Nextpoint Therapeutics, Inc. is a biotech company based in Cambridge, MA. The company is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. The company's innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Nextpoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies. Detlev Biniszkiewicz has been the CEO of the company since 2018. | Miscellaneous Commercial Services | Director/Board Member Chairman Director/Board Member | |
| TURMERIC ACQUISITION CORP. | Financial Conglomerates | Chief Executive Officer Director/Board Member Chairman | |
Cullinan Mica Corp.
 Cullinan Mica Corp. Pharmaceuticals: MajorHealth Technology Part of Cullinan Therapeutics, Inc., Cullinan Mica Corp. is a private company that provides worldwide rights to CLN-619. The company is based in Cambridge, MA. The CEO of the company is Nadim Ahmed. | Pharmaceuticals: Major | Director/Board Member Chief Executive Officer | |
LifeEDIT Therapeutics, Inc.
 LifeEDIT Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Part of ElevateBio LLC, LifeEDIT Therapeutics, Inc. is a next-generation genome editing private company that has built a highly innovative platform with one of the world's largest and most diverse collections of novel RNA-guided nucleases (RGNs) and base editors. The company offers gene editing tools with higher fidelity, novel functionality, reduced immune response risk, and easier delivery. LifeEDIT has a large and diverse library of RGNs, including type II and type V systems that encompass knock-out and knock-in capabilities, transcriptional regulation, and base editing when coupled with one of their proprietary deaminases. The company's nuclease collection has a broad range of protospacer adjacent motifs (PAMs), offering unprecedented access to genomes. LifeEDIT is headquartered in Morrisville, NC. The CEO of the company is Mitchell H. Finer. LifeEDIT Therapeutics was acquired by ElevateBio LLC from AgBiome Delta LLC on October 27, 2021. | Miscellaneous Commercial Services | Director/Board Member Chief Executive Officer Director/Board Member | |
Renagade Therapeutics, Inc.
 Renagade Therapeutics, Inc. BiotechnologyHealth Technology Renagade Therapeutics, Inc. is an American US-based company that aims to overcome the limitations of RNA medicines by applying their comprehensive deliver, code, edit, insert technologies to precisely correct disease on an unprecedented scale. The company has developed a broad portfolio of RNA delivery systems, which profoundly expand the array of addressable diseases. The company's proprietary, synergistic toolkit allows them to precisely deliver, code, edit, and insert RNA medicines to treat any disease, anywhere in the body. Renagade is built on a foundation of proprietary delivery technologies to unlock previously inaccessible cells, reprogramming cells with superior expression using the leading RNA coding platform via joint venture with Orna Therapeutics, enabling curative therapies by permanently correcting defective genes with proprietary technology, and industry-leading all-RNA system to enable exon or large gene insertions as a gene therapy 2.0 platform. Renagade is backed by MPM BioImpact and F2 Ventures, leading financial groups who have supported the development of over 50 products to market. | Biotechnology | Director/Board Member Director/Board Member Founder | |
| ADAPTIMMUNE THERAPEUTICS PLC | Biotechnology | Chief Operating Officer Director/Board Member Corporate Officer/Principal |
Statistieken
Internationaal
| Verenigde Staten | 44 |
| Verenigd Koninkrijk | 4 |
| Duitsland | 2 |
| Zwitserland | 2 |
| België | 2 |
Sectoraal
| Health Technology | 28 |
| Consumer Services | 13 |
| Finance | 6 |
| Health Services | 4 |
| Commercial Services | 4 |
Operationeel
| Director/Board Member | 524 |
| Corporate Officer/Principal | 229 |
| Independent Dir/Board Member | 161 |
| Chief Executive Officer | 120 |
| Chairman | 90 |
Sterkste connecties
| Insiders | |
|---|---|
| Luke Evnin | 42 |
| Kurt von Emster | 34 |
| Thomas Ebeling | 33 |
| Dieter Weinand | 32 |
| Michael Wyzga | 31 |
| Jeffrey Bornstein | 26 |
| Briggs Morrison | 26 |
| Mitchell Finer | 26 |
| James Tobin | 26 |
| Robert Williamson | 25 |
| Robert M. Forrester | 25 |
| Michael Kauffman | 24 |
| Owen Hughes | 23 |
| Anthony Adam Rosenberg | 23 |
| Jake Nunn | 23 |
- Beurs
- Insiders
- Ansbert Gadicke
- Bedrijfsconnecties
